← All trials
NCT00344318
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2006
- Primary completion
- Apr 1, 2007
- Completion date
- Oct 1, 2007
- First posted
- —
- Last posted
- —
- Enrollment
- 806
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
Drugs studied
- pneumococcal 13-valent conjugate vaccine
- tritanrix-hepb
- tritanrix-hepb
- live oral poliovirus type 1, 2 and 3
- live oral poliovirus type 1, 2 and 3
- pneumococcal 7-valent conjugate vaccine
- haemophilus influenzae type b conjugate vaccine
- haemophilus influenzae type b conjugate vaccine
- polio, inactivated poliovirus vaccine
- polio, inactivated poliovirus vaccine
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.